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bjectives This study was conducted to determine whether direct stenting with TAXUS Liberté is
oninferior to stenting after pre-dilation.
ackground Direct stenting is performed in approximately 30% of patients, but data on clinical and
ngiographic outcomes with drug-eluting stents are limited.
ethods The TAXUS ATLAS DIRECT STENT is a single-arm, multicenter study that enrolled patients
ith de novo coronary lesions visually estimated to be 10 to 28 mm in length in vessels 2.5 to 4.0
m in diameter. The control group is the quantitative coronary angiography (QCA) subset of the
AXUS ATLAS trial, which used identical inclusion and exclusion criteria but mandated pre-dilation.
he primary end point is 9-month analysis-segment percent diameter stenosis (%DS).
esults Baseline patient characteristics were similar between the groups. On QCA analysis, signiﬁ-
antly shorter lesions with larger lumen diameter and less calciﬁcation were observed in the direct
tent group. Direct stenting was successful in 97.6% of patients and was associated with a shorter
rocedure time and fewer complications. Follow-up %DS was noninferior for direct stent (26.41%)
ersus pre-dilation (29.14%) with a 1-sided 95% conﬁdence interval of the difference between the
roups (0.34%) well below the pre-speciﬁed noninferiority margin (6.75%). Additionally, signiﬁ-
antly lower restenosis (5.9% vs. 11.4%, p  0.0229) and target lesion revascularization (TLR) 2.9%
s. 7.8%, p  0.0087) rates were seen for direct stent versus pre-dilation.
onclusions Direct stenting of TAXUS Liberté is feasible and highly successful in carefully selected
esions. Direct stenting is noninferior to stenting after pre-dilation on the basis of %DS and can sig-
iﬁcantly reduce procedural time, procedural complications, and possibly angiographic restenosis
nd TLR. (TAXUS Liberté-SR Paclitaxel-Eluting Coronary Stent System; NCT00371423). (J Am Coll
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151onventional stenting generally employs balloon pre-
ilation of the target lesion to simplify stent delivery and
acilitate complete stent expansion. The introduction of
ore flexible, lower-profile, balloon-expandable stents has
ade direct stenting (i.e., without pre-dilation) more com-
on. Studies using bare metal stents have proven that direct
tenting is safe and effective in patients selected for favorable
natomy, with outcomes similar to stenting after pre-
ilation but with reduced procedural time and cost (1–5).
Drug-eluting stents have demonstrated a clear benefit over
are metal stents in suppressing neointimal growth and reduc-
ng the rate of repeat revascularization, resulting in better
ong-term outcomes even in complex lesions (6–8). Similar to
he bare-metal stent experience, drug-eluting stents are im-
lanted without pre-dilation in up to 34% of patients (9–11).
here are few data from controlled trials on direct stenting
ith drug-eluting stents, beyond early evidence suggesting it to
e as safe as stenting after pre-dilation (12–14).
The TAXUS Liberté stent (Boston Scientific Corpora-
ion, Natick, Massachusetts) combines the polymer-based,
aclitaxel-eluting TAXUS technology with a more ad-
anced stent geometry and was proven to be effective in the
ivotal TAXUS ATLAS study (15). The TAXUS Liberté
eatures thinner 316L stainless steel struts (0.0038 vs.
.0052 inches); a continuous cell architecture for improved
eliverability, conformability, and homogeneity of drug
istribution; and a smaller tip profile to allow easier access to
he target lesion (16). The TAXUS ATLAS DIRECT
TENT was a prospective, single-arm, historically con-
rolled study evaluating the hypothesis that direct stenting
ith TAXUS Liberté is noninferior to stenting with balloon
re-dilation.
ethods
evice description. The TAXUS Liberté-SR Stent consists
f a balloon-expandable Liberté stent with a polymer
oating containing 1 g/mm2 of paclitaxel in a slow-release
ormulation.
atient selection, procedure, and follow-up. A total of 247
irect stent patients were enrolled at 24 centers in the U.S.,
ew Zealand, and Singapore from March to September
005. The study protocol was approved by local ethics
eview committees, and all patients provided written in-
ormed consent. Trial results are reported on the National
nstitutes of Health website (see registry information after
he abstract).
Eligible patients were 18 years or older undergoing
ercutaneous coronary intervention of a single de novo
rants from Boston Scientific Corporation. Dr. Ormiston is on the advisory board of
stockholder of Boston Scientific Corporation. Drs. Mandiov and Baim are full-timeanuscript received November 1, 2007; revised manuscript received January 18, 2008, accesion 10 and 28 mm in length (visual estimate) in a
ative coronary artery with a reference vessel diameter
RVD) of 2.5 and 4.0 mm (visual estimate) and a left
entricular ejection fraction of 25%. Patients with myo-
ardial infarction within 72 h were prohibited. Angio-
raphic exclusion criteria prohibited left main, ostial, or
ifurcation lesions; total occlusion or thrombus; severe or
oderate lesion calcification; and tortuosity or excessive
ending. Enrollment occurred after successful treatment of
non-target lesion (if applicable) but before advancing a
uidewire across the target lesion.
Loading doses of clopidogrel (300 mg) or ticlopidine (500
g), and aspirin (300 mg) were administered before the
rocedure. After stent implantation, all patients were pre-
cribed clopidogrel (75 mg daily)
r ticlopidine (250 mg twice
aily) for a minimum of 6
onths. Aspirin (100 mg
aily) was mandated for at least
months and recommended in-
efinitely.
Clinical follow-up was sched-
led at 1, 4, and 9 months and
early thereafter for 5 years.
uantitative coronary angiogra-
hy (QCA) and intravascular ul-
rasound (IVUS) follow-up for
ll patients were scheduled at 9
onths.
ontrol group. The 543 patients
rom the QCA subset of the
ivotal TAXUS ATLAS study
erved as the pre-dilation control
or TAXUS ATLAS DIRECT
TENT (15). Inclusion and ex-
lusion criteria were identical for
AXUS ATLAS and TAXUS
TLAS DIRECT STENT.
nrollment, however, occurred
fter successful pre-dilation of
he target lesion in TAXUS ATLAS but before wiring of
he target lesion in TAXUS ATLAS DIRECT STENT.
dditionally, whereas all direct stent patients were required
o have both IVUS and QCA follow-up at 9 months, only
subset of pre-dilation control subjects underwent IVUS
ollow-up (Fig. 1).
eﬁnitions. Major adverse cardiac events (MACE) and
tent thromboses were adjudicated by an independent Clin-
cal Events committee. The clinical and angiographic end
n Scientific Corporation. Dr. Baim is
yees of Boston Scientific Corporation.
Abbreviations
and Acronyms
%DS  percent diameter
stenosis
ARC  Academic Research
Consortium
CI  confidence interval
HR  hazard ratio
ITT  intention-to-treat
IVUS  intravascular
ultrasound
MACE  major adverse
coronary events
MLD  minimum lumen
diameter
PP  per-protocol
QCA  quantitative coronary
angiography
RVD  reference vessel
diameter
TLR  target lesion
revascularization
TVR  target vessel
revascularizationepted January 20, 2008.
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152oint definitions were identical to those in TAXUS ATLAS
15). Stent thrombosis was determined angiographically or,
n the absence of angiographic confirmation, as sudden
ardiac death within 30 days of implantation or myocardial
nfarction in the territory of the target vessel, with a protocol
efinition that closely parallels the Academic Research
onsortium (ARC) definite or probable criteria.
The QCA and IVUS analyses were performed by the
ame core laboratories (Brigham and Women’s Hospital,
oston, Massachusetts, and Washington Hospital Center,
ashington, DC, respectively) for both TAXUS ATLAS
IRECT STENT and TAXUS ATLAS (15). Both QCA
nd IVUS measures within the stent and the analysis
egment (including the stented region and the 5-mm edge
egions) were reported separately. Paired analyses were
onducted on patients for whom both procedure and
-month data were available.
nd points. The primary end point was percent diameter
tenosis (%DS) of the analysis segment at 9 months.
econdary end points included MACE, stent thrombosis,
ll-cause death, and QCA and IVUS outcomes.
tatistical methodology. All end points were analyzed with
oth the intention-to-treat (ITT) and the per-protocol (PP)
opulation, which excluded patients who did not receive
ither the study stent or the assigned implantation proce-
ure. The PP population was the main population of
nterest for noninferiority testing of the primary end point
o eliminate possible dilution of the true differences between
he assigned stent and implantation procedures, thus
reventing erroneous conclusions. The pre-specified non-
nferiority margin of 6.75% was based on one-half of the
Figure 1. TAXUS ATLAS DIRECT STENT Study Flow
*Only 60% of pre-dilation control patients versus 100% of direct stent patients
months, only per-protocol population (PP) patients will continue to be followeffect exhibited by the TAXUS Express stent versus the Tare metal control in the TAXUS IV trial (8). Assuming
noninferiority margin of 6.75%, a 9-month %DS
nalysis segment rate of 26.3% (on the basis of TAXUS
V), and 30% attrition, the required enrollment for
AXUS ATLAS DIRECT STENT was 250 subjects for
9% power.
Baseline, post-procedure, and follow-up information
ere summarized with descriptive statistics. The p value for
omparing 2 independent continuous variables was from
tudent t test and for comparing 2 proportions was from the
hi-square test; Fisher exact test was used if the total
umber of samples was 40 or at least 1 cell count in the 2
2 table was expected to be 5. The Kaplan-Meier
roduct-limit method and log-rank test were used to assess
ime-to-event end points across study groups.
Propensity score analysis was performed with a hierarchi-
al logistic regression model with a stepwise selection
rocess. The significance level for entry and exit of inde-
endent variables was set at 0.10. Multivariate analysis was
sed to determine predictors for target lesion revasculariza-
ion (TLR) at 9 months. All covariates were modeled
nivariately for each outcome and multivariately with a
tepwise procedure in an appropriate regression model.
tatistical significance was set at p  0.05.
esults
aseline characteristics. The groups were well-matched for
emographic data and clinical characteristics, but direct
tent patients had shorter lesions, larger minimum lumen
iameter (MLD), less %DS, and less calcification (Table 1).
included in the intravascular ultrasound (IVUS) subset; †starting at 12
io  angiography; F/U  follow-up; ITT  intent-to-treat.werehere was a high prevalence of type B2/C lesions in both
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153roups. For both groups, 50% of target lesions were 13
m in length, but 95% of lesions were 23.5 mm (maxi-
um 31.1 mm) for the direct stent group, versus 95% of
esions being28 mm for the control (maximum 52.7 mm),
ndicating a skew toward shorter lesions for the direct stent
roup (Fig. 2).
rocedural outcomes. The TAXUS Liberté stent was suc-
Table 1. Baseline Patient and Lesion Characteristics
Pre-Dilation Control
(n  543)
Male 68.1% (370/543)
Age (yrs) 61.9  10.7 (543)
Cardiac history
Stable angina 58.7% (319/543)
Unstable angina 33.3% (181/543)
Silent ischemia 7.9% (43/543)
Previous MI 27.4% (149/543)
Previous PCI 28.4% (154/543)
Cardiac risk factors
Current smoking 25.2% (137/543)
Diabetes, medically treated 26.0% (141/543)
Hypertension 72.9% (396/543)
Hyperlipidemia 75.9% (412/543)
Lesion characteristics (by QCA)
Target lesion vessel
LAD 41.6% (226/543)
LCX 25.4% (138/543)
RCA 33.0% (179/543)
Lesion location
Ostial 2.8% (15/543)
Proximal 39.2% (213/543)
Mid 51.0% (277/543)
Distal 7.0% (38/543)
RVD (mm) 2.76  0.50 (543)
MLD (mm) 0.84  0.36 (543)
%DS 69.47  12.02 (543)
Lesion length (mm) 15.08  6.81 (543)
Bend 45° 27.8% (151/543)
Tortuosity 13.1% (71/543)
Calciﬁcation 31.7% (172/543)
Moderate 26.3% (143/543)
Severe 5.3% (29/543)
Branch vessel disease 11.6% (63/541)
Modiﬁed ACC/AHA lesion type
A 5.3% (29/543)
B1 16.6% (90/543)
B2 44.4% (241/543)
C 33.7% (183/543)
B2 or C‡ 78.1% (424/543)
Numbers are % (count/sample size) or mean SD (n). *p values were calculated by Student t test o
was not included in the calculation of the overall p value for the American College of Cardiology (A
CABG  coronary artery bypass graft; CAD  coronary artery disease; DS  diameter stenosis;
minimum lumen diameter; PCI percutaneous coronary intervention; QCA quantitative coronaessfully implanted by direct stenting in 97.6% of direct ptent patients, with crossover to balloon pre-dilation re-
uired in only 6 patients (2.4%; Table 2). One control
atient (0.2%) underwent direct stenting. All 247 direct
tent patients (100%) and 539 (99.3%) control patients
uccessfully received the TAXUS Liberté stent. A mean of
.1 stents/patient was implanted in both groups (591 stents
n 543 control patients; 269 stents in 247 direct stent
Direct Stent
(n  247) p Value*
70.4% (174/247) 0.52
61.5  10.6 (247) 0.61
57.9% (143/247) 0.82
35.6% (88/247) 0.53
6.5% (16/247) 0.47
30.8% (76/247) 0.34
29.6% (73/247) 0.73
25.9% (64/247) 0.84
22.7% (56/247) 0.32
66.0% (163/247) 0.0469
75.3% (186/247) 0.86
0.17†
46.6% (115/247) 0.19
27.1% (67/247) 0.61
26.3% (65/247) 0.06
0.90†
3.2% (8/247) 0.71
41.3% (102/247) 0.58
49.0% (121/247) 0.60
6.5% (16/247) 0.79
2.80  0.46 (247) 0.25
0.91  0.35 (247) 0.0081
67.40  10.93 (247) 0.0215
13.87  36 (247) 0.0133
27.1% (67/247) 0.84
10.1% (25/247) 0.24
23.5% (58/247) 0.0188
21.5% (53/247) 0.15
2.0% (5/247) 0.0367
15.2% (37/244) 0.17
0.14†
4.9% (12/247) 0.78
22.3% (55/247) 0.0554
45.7% (113/247) 0.72
27.1% (67/247) 0.06
72.9% (180/247) 0.11
uare test unless otherwise noted. †p values calculated by Fisher exact test. ‡The B2 or C category
erican Heart Association (AHA) lesion type.
left anterior descending artery; LCX  left circumflex (artery); MI  myocardial infarction; MLD 
graphy; RCA right coronary artery; RVD reference vessel diameter.r chi-sq
CC)/Am
LAD atients). The majority of implanted stents were 3.0 mm in
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154iameter (32.0% control; 45.4% direct stent) and 16 mm in
ength (37.4% control; 50.9% direct stent). There were no
pisodes of stent detachment or embolization in the direct
tent group.
Procedural time was similar between the groups (Table
). However, 100% of direct stent patients but only
0.2% of control patients were included in the IVUS
ollow-up. For those patients in the IVUS subset, both
rocedure and fluoroscopy time were significantly shorter
Figure 2. Cumulative Frequency Distribution of Baseline Lesion Length as
Median and 95th percentile lengths are shown. QCA  quantitative coronary a
Table 2. Procedural Characteristics and Success
Pre-Dilation Co
(n  543
Procedure time (min) 51.0 26.9 (5
Procedure time  IVUS subset† (min) 57.5 25.9 (3
Fluoroscopy time  IVUS subset† (min) 12.8 8.3 (32
Pre-dilation 99.8% (542/5
Maximum pressure overall (atm) 15.8 3.4 (54
Maximum balloon/artery ratio‡ 1.2 0.1 (54
Maximum device size (mm) 3.2 0.6 (54
Post-dilation 49.7% (270/5
Multiple stents implanted 9.0% (49/54
Technical and procedural performance
Successful direct stenting n/a
Clinical procedural success§ 96.7% (525/5
Procedural complications 3.1% (17/54
Abrupt closure 0.9% (5/540
No reﬂow 0.6% (3/540
Dissection 2.4% (13/54
Others 1.1% (6/541
Numbers shown aremean SD (n) or% (count/sample size). *p valueswere calculated by Student t
a subset of pre-dilation control patients were assigned to the IVUS subset. ‡Maximum balloon size
TIMI flow grade 3, as visually assessed by the Investigator, without the occurrence of MACE as of th
perforation, or post-procedure thrombus. ¶p values calculated by Fisher exact test.IVUS intravascular ultrasound; MACEmajor adverse cardiac events; QCA quantitative coronary anor direct stent versus control by nearly 5 and 2 min,
espectively. Maximum stent-deployment inflation pres-
ure was similar between the groups. Post-dilation was
erformed 13.0% more frequently for the direct stent
roup (Table 2). The maximum balloon/artery size ratio
nd the overall maximum device size were both signifi-
antly smaller for direct stent than control. There were
ignificantly fewer complications in the direct stent group
han the control (Table 2).
ined by QCA
raphy.
Direct Stent
(n  247)
p
Value*
52.8 21.9 (246) 0.35
52.8 21.9 (246) 0.0226
10.9 6.1 (246) 0.0034
2.4% (6/247) 0.0001
16.0 3.0 (247) 0.28
1.1 0.1 (247) 0.0001
3.1 0.4 (247) 0.0012
62.8% (155/247) 0.0007
8.1% (20/247) 0.67
97.6% (241/247) n/a
96.8% (239/247) 0.96
0.4% (1/247) 0.0170
0.4% (1/246) 0.67¶
0.0% (0/247) 0.56¶
0.0% (0/247) 0.0124¶
0.0% (0/247) 0.18¶
hi-square test unless otherwise noted.†All direct stent patients were to receive IVUS, whereas only
ator-reported; RVD from core lab QCA. §Defined as mean lesion diameter stenosis of30% with
f hospital discharge. Defined as the occurrence of no reflow, abrupt closure, dissection, embolus,Determntrol
)
42)
26)
7)
43)
3)
3)
3)
43)
3)
43)
1)
)
)
0)
)
test or c
investig
e time ogiography; RVD reference vessel diameter.
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155ntiplatelet use. At hospital discharge, 99.6% of pre-
ilation control subjects and 100% of direct stent patients
ere receiving dual antiplatelet therapy (p  1.00). A
otal of 91.6% of pre-dilation control patients and 93.3%
f direct stent patients (p  0.40) received dual anti-
latelet therapy through the protocol-mandated 6-month
uration. By 9 months, the use of dual antiplatelet
herapy had fallen to 60.5% for pre-dilation and 57.9%
or direct stent (p  0.49); however, 94.7% of control
atients and 97.9% of direct stent patients (p  0.0410)
ere taking aspirin.
-month angiographic diameter stenosis. The primary end
oint of noninferiority of analysis segment %DS was ana-
yzed for both the ITT and PP populations (Fig. 3). The PP
opulation exhibited unadjusted %DS values of 29.14% for
he control and 26.41% for the direct stent group. The
ifference in %DS values between the groups was 2.73%,
nd the upper 1-sided 95% confidence interval (CI) of this
ifference was 0.34%, which is significantly less than the
re-specified noninferiority margin of 6.75% (p  0.0001);
hus, noninferiority of direct stenting versus pre-dilation
as demonstrated. Similar results were obtained with the
TT population and after propensity score adjustment for
ifferences in baseline characteristics.
ngiographic and IVUS paired lesion analysis. At 9 months,
aired lesion QCA analysis demonstrated similar MLD,
DS, and late loss in both groups (Table 3).
The IVUS analysis revealed no differences between the
roups for changes in vessel, lumen, or neointima area from
ost-procedure to 9 months. The percent in-stent net
olume obstruction and the percent neointima-free length
f the stent were also similar (Table 3). Additionally, both
Figure 3. Primary End Point: 9-Month Analysis Segment %DS
(A) Unadjusted (Unadj) and propensity score-adjusted (Adj) rates are shown fo
end point is based on the adjusted PP analysis. (B) Schematic representation o
pre-speciﬁed noninferiority margin, difference (Diff) between the control and direct sroups showed comparable rates for early (direct stent: 8.7%
22 of 254]; control: 6.2% [12 of 193]; p  0.33) and late
ncomplete apposition (direct stent: 4.3% [9 of 209]; con-
rol: 3.9% [7 of 180]; p  0.84).
Despite similar amounts of neointimal hyperplasia, late
oss, and %DS between the groups, binary angiographic
estenosis rates were reduced significantly for direct stent
ersus the control, even after propensity score adjustment
Fig. 4). The restenosis rates remained similar between
he groups at the proximal and distal edges, but direct
tenting was associated with a significant reduction of
ocal in-stent restenosis compared with control. The
revalence of diffuse, proliferative, and totally occluded
n-stent restenosis was low and comparable for the groups
Fig. 4).
linical outcomes through 9 months. Early MACE rates
ere comparable between groups (in-hospital control 2.6%,
irect stent 3.2%, p  0.60; 30-day control 3.1%, direct
tent 3.3%, p  0.93). However, 9-month MACE rates
ere significantly lower for direct stent than control (Table
). This difference was mainly attributable to a 70% reduc-
ion in TLR for direct stent versus control. The groups were
imilar for myocardial infarction, cardiac death, and non-
ardiac and total death. Of note, adjusted target vessel
evascularization (TVR) and TLR rates were concordant
ith the unadjusted rates (Table 5).
2-month clinical outcomes. At 12 months, the direct stent
roup exhibited a sustained 70% reduction for TLR versus
he control, which was reflected in a 63% reduction of both
VR and MACE (Fig. 5). Propensity score adjusted rates
ere concordant with the unadjusted rates (Table 5).
dditionally, the reduction in TLR was not affected by
the intention-to-treat (ITT) and per-protocol (PP) populations. The primary
inferiority testing results of analysis segment % diameter stenosis (%DS). Ther both
f nontent values, and upper 1-sided 95% conﬁdence interval (CI) are presented.
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156reater use of post-dilation in the direct stent group (data
ot shown).
Throughout the 12-month follow-up, there were no
pisodes of stent thrombosis in the direct stent group versus
n incidence of 1.1% in the control. After propensity score
djustment, this difference was statistically significant. The
RC definite or probable stent thrombosis was 0.0% for
irect stent versus 1.5% (8 of 523) for pre-dilation control
p  0.0635).
redictors of TLR. Multivariate modeling identified RVD,
tent expansion index, and implantation technique as pre-
ictors of 12-month TLR. Smaller vessels increased the risk
or TLR (1.24; hazard ratio [HR] 0.29, 95% CI 0.13 to
.62; p  0.0015), such that for each 1-mm decrease in
aseline RVD, there was a 29% increased risk for TLR. The
tent expansion index was also a negative predictor for TLR
0.04; HR 0.96, 95% CI 0.93 to 0.99; p  0.018), with
% underexpansion resulting in a 4% increased risk of TLR.
Table 3. Angiographic and IVUS Outcomes: Paired Lesion Analysis
Pre-Dilation C
(n  543
Pre-procedure QCA
RVD (mm) 2.77 0.50 (
MLD (mm) 0.83 0.36 (
%DS 69.92 11.88
Post-procedure QCA
RVD (mm) 2.82 0.52 (
MLD, in-stent (mm) 2.60 0.46 (
MLD, analysis segment (mm) 2.22 0.51 (
%DS, in-stent 7.30 8.87 (
%DS, analysis segment 21.30 9.47 (
Acute gain, in-stent (mm) 1.77 0.48 (
Acute gain, analysis segment (mm) 1.39 0.50 (
9-month QCA
RVD (mm) 2.75 0.49 (
MLD, in-stent (mm) 2.19 0.71 (
MLD, analysis segment (mm) 1.97 0.67 (
%DS, in-stent 21.04 21.40
%DS, analysis segment 29.15 19.06
Late loss, in-stent (mm) 0.41 0.54 (
Late loss, analysis segment (mm) 0.25 0.50 (
Loss index, in-stent 0.25 0.37 (
Loss index, analysis segment 0.20 0.57 (
9-month IVUS
Change in mean vessel area (mm2) 0.79 1.26 (
Change in mean lumen area (mm2) 0.92 1.10 (
Change in mean neointimal area (mm2) 1.02 0.94 (
In-stent net volume obstruction (%) 13.55 11.13
Neointimal free length of stent (%) 63.96 33.15
Data shown are for paired analysis subset, including patients for whom both procedure and 9-mon
t test.
Abbreviations as in Tables 1 and 2.inally, direct stenting was an independent negative predic- sor for TLR (0.97; HR 0.38, 95% CI 0.17 to 0.86; p 
.0204) and corresponded to a 38% risk reduction for TLR.
iscussion
he TAXUS ATLAS DIRECT STENT demonstrates
hat direct deployment of TAXUS Liberté in selected
atients is feasible and can shorten procedural times versus
re-dilation while decreasing the rate of procedural compli-
ations in simpler lesions. Neointimal hyperplasia was
imilar after both direct stenting with TAXUS Liberté and
tenting with pre-dilation, but direct stenting was associated
ith reduced rates of binary angiographic restenosis and
schemia-driven TLR. There was also a trend for a reduced
isk of stent thrombosis in the first year after direct stent
mplantation. However, it is unclear whether these benefits
re due to direct stenting itself or to the favorable vessel and
esion characteristics that led to selection for the direct
Direct Stent
(n  247) p Value*
2.81 0.46 (221) 0.32
0.91 0.35 (221) 0.0073
67.70 10.85 (221) 0.0197
2.86 0.48 (221) 0.29
2.67 0.43 (221) 0.0582
2.30 0.47 (221) 0.0517
6.23 8.82 (221) 0.14
19.61 8.52 (221) 0.0257
1.76 0.46 (221) 0.84
1.39 0.46 (221) 0.97
2.77 0.44 (221) 0.58
2.27 0.57 (221) 0.14
2.05 0.55 (221) 0.11
18.25 16.05 (221) 0.09
26.42 14.07 (221) 0.0597
0.40 0.44 (221) 0.76
0.25 0.41 (221) 0.91
0.23 0.27 (221) 0.49
0.17 0.34 (221) 0.35
0.88 1.29 (126) 0.57
0.74 1.03 (144) 0.14
1.06 0.94 (144) 0.68
14.33 11.87 (144) 0.55
64.86 32.29 (144) 0.81
were available. Numbers shown are mean SD (n) or % (n). *p values were calculated by Studentontrol
)
449)
449)
(449)
447)
446)
447)
446)
447)
446)
447)
449)
448)
449)
(448)
(449)
446)
447)
446)
447)
154)
177)
177)
(177)
(177)
th datatenting group.
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157With the advent of more deliverable stents, direct stenting
as become increasingly common. As a thin-strut drug-eluting
tent with a lower profile and increased flexibility for enhanced
eliverability and conformability, TAXUS Liberté is suitable
or direct stenting in selected patients. Indeed, direct stenting
as successful in 97.6% of patients in this study, which is
imilar to the best results reported with bare metal stents in
omewhat simpler lesions (1–5).
A major benefit of direct stenting is a significant reduc-
ion in procedure time and radiation exposure (1-5). How-
ver, direct stenting might lead to errors in stent placement
ecause of limited vessel opacification, incorrect stent sizing,
nderexpansion, or incomplete strut apposition. Stent dis-
Figure 4. Binary Restenosis Edge Analysis
Nine-month results from the intention-to-treat population are shown. (A) Unad
edge. In-stent restenosis patterns are also indicated for the in-stent segment. (
segment. D  diffuse; F  focal; P  proliferative; TO  total occlusion.
Table 4. 9-Month Clinical Outcomes in the Intention-to-Treat Population
Unadjusted
Pre-Dilation Control
(n  543)
Direct Stent
(n  247)
MACE 14.7% (79/537) 9.1% (22/242)
Cardiac death 1.3% (7/537) 0.8% (2/242)
MI 4.3% (23/537) 4.5% (11/242)
Q-wave 0.9% (5/537) 0.4% (1/242)
Non–Q-wave 3.4% (18/537) 4.1% (10/242)
TVR, overall 11.2% (60/537) 5.0% (12/242)
TLR 7.8% (42/537) 2.9% (7/242)
TVR, remote 4.5% (24/537) 2.9% (7/242)
TVF 14.3% (77/537) 8.7% (21/242)
Stent thrombosis 0.9% (5/533) 0.0% (0/240)
Numbers shown are % (count/total). *p values were calculated by chi-square test unless otherwiseMACEmajor adverse cardiac events; MImyocardial infarction; TLR target lesion revascularizationodgement and embolization are theoretical possibilities
ither at the lesion site or upon withdrawal of an unsuc-
essfully attempted stent placement. Thus, direct stenting
ight increase procedural risk or suboptimal late clinical
utcomes. In the present study, the benefits of reduced
rocedural time and radiation exposure were confirmed for
AXUS Liberté without any potential adverse conse-
uences. In particular, the occurrence of incomplete appo-
ition was low and comparable between the groups. The
tent expansion index was similar in both groups, and
rocedural complications such as no reflow, distal emboli-
ation, dissection, or thrombus formation were significantly
educed after direct stenting versus pre-dilation. Thus,
binary restenosis rates for the proximal edge, in-stent segment, and distal
adjusted and propensity score-adjusted binary restenosis rates of the analysis
Adjusted
lue*
Pre-Dilation Control
(n  543)
Direct Stent
(n  247) p Value†
307 14.6% 10.1% 0.09
3‡ 1.3% 1.0% 0.69
7 4.1% 5.7% 0.41
7‡ 1.0% 0.3% 0.18
9 3.2% 5.5% 0.22
056 11.1% 5.4% 0.0062
087 7.7% 3.2% 0.0064
0 4.4% 2.9% 0.32
275 14.2% 9.9% 0.10
3‡ 0.96% 0.0% 0.0269
†p values were calculated by Student t test. ‡p values calculated by Fisher exact test.justed
B) Unp Va
0.0
0.7
0.8
0.6
0.5
0.0
0.0
0.3
0.0
0.3
noted.; TVF target vessel failure; TVR target vessel revascularization.
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158AXUS ATLAS DIRECT STENT demonstrates that
irect stenting can be a safe implantation technique for
rug-eluting stents and might decrease the occurrence of
rocedural complications in selected lesions.
It is important to underscore that patients were carefully
elected for direct stenting. The QCA analysis revealed that
5% of lesions were23.5 mm in the direct stent group but
28 mm in the pre-dilation group, indicating that longer
esions were clearly avoided for direct stenting. Lesion
alcification was significantly less in the direct stent group,
ith only 2% of direct stent lesions severely calcified.
dditionally, stenosis severity in the direct stent group was
ess than in the pre-dilation group. However, with more
han 70% of lesions classified as American College of
ardiology/American Heart Association type B2 or C, the
Table 5. 12-Month Clinical Outcomes in the Per-Protocol Population
Unadjusted
Pre-Dilation Control
(n  543)
Direct Stent
(n  247)
MACE 16.3% (86/528) 8.9% (21/237)
Cardiac death 1.3% (7/528) 0.8% (2/237)
MI 4.5% (24/528) 4.2% (10/237)
Q-wave 0.9% (5/528) 0.4% (1/237)
Non–Q-wave 3.6% (19/528) 3.8% (9/237)
TVR, overall 12.5% (66/528) 4.6% (11/237)
TLR 8.3% (44/528) 2.5% (6/237)
TVR, remote 5.5% (29/528) 3.0% (7/237)
TVF 15.9% (84/528) 8.4% (20/237)
Stent thrombosis 1.1% (6/523) 0.0% (0/235)
Total death 1.5% (8/528) 0.8% (2/237)
Noncardiac death 0.2% (1/521) 0.0% (0/235)
Numbers shown are % (count/total). *p values were calculated by chi-square test unless otherwise
MACEmajor adverse cardiac events; MImyocardial infarction; TLR target lesion revascula
Figure 5. Freedom From TLR Through 1 YearTLR  target lesion revascularization.esions treated in this study are the most complex enrolled in
ny direct stenting study to date (1–3,5).
Preclinical studies have suggested that direct stenting
ight be less traumatic than stenting after pre-dilation in
hat it limits endothelial denudation, edge injury, and
he occurrence of dissections or thrombus formation
17,18). Rogers et al. (17) demonstrated that the vascular
esponse to stent implantation in arteries denuded by
alloon pre-dilation, including monocyte recruitment, re-
ndothelialization, and neointima development, can be
ramatically reduced by direct stenting, which leaves some
emnant endothelium. Presumably, this can increase the
peed of regeneration of an intact endothelial monolayer
nd reduce the requirement for endothelial proliferation and
igration. However, randomized clinical trials evaluating
Adjusted
lue*
Pre-Dilation Control
(n  543)
Direct Stent
(n  247) p Value†
062 16.2% 9.9% 0.0186
3‡ 1.4% 1.2% 0.87
4 4.4% 5.3% 0.63
7‡ 1.0% 0.3% 0.17
9 3.4% 5.0% 0.38
008 12.5% 4.8% 0.0003
027 8.2% 2.6% 0.0006
2 5.5% 3.0% 0.11
053 15.7% 9.6% 0.0207
8‡ 1.2% 0.0% 0.0151
3‡ 1.6% 1.2% 0.72
0‡ 0.2% 0.0% 0.31
†p values were calculated by Student t test. ‡p values calculated by Fisher exact test.
; TVF target vessel failure; TVR target vessel revascularization.p Va
0.0
0.7
0.8
0.6
0.8
0.0
0.0
0.1
0.0
0.1
0.7
1.0
noted.
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159irect stenting of bare metal stents have failed to show a
onsistent benefit in reducing angiographic restenosis or
LR versus stenting after pre-dilation (1–3,5). Therefore,
AXUS ATLAS DIRECT STENT is one of the first
tudies to report a beneficial effect of direct stenting on
inary restenosis and the need for TLR (48% and 70%
elative reduction, respectively, at 9 months).
The conflicting impact of direct stenting on TLR and
estenosis between the current study and previous bare metal
tent studies might be due to differences in vascular healing
fter implantation of drug-eluting stents versus bare metal
tents. Because drug-eluting stents are associated with
elayed endothelialization versus bare metal stents, leaving
reas of intact endothelium might be more important for
rug-eluting stents than bare metal stents. In support of this
oncept, there was a significant reduction of TLR after
irect stenting with drug-eluting stents in a recent small
andomized trial (19) and a trend for reduced revasculariza-
ion in an ad hoc analysis of the sirolimus-eluting stent (13).
his outcome might also result from reduced local dissec-
ion and post-procedural thrombus after direct stenting, as
uggested in this study and by others (17,18). Alternatively,
esions treated in the present study were of higher complex-
ty than those previously studied, so a less traumatic ap-
roach might have had a greater effect on these more
omplex lesions. Conversely, although direct stenting re-
ained a predictor of lower TLR rates after multivariate
odeling, we cannot exclude the confounding effect of the
lightly shorter lesion length and larger MLD in the direct
tent cohort or associated lesion factors that might also have
ontributed to reduced restenosis. Further studies are nec-
ssary to clarify these hypotheses.
tudy limitations. The TAXUS ATLAS DIRECT
TENT is a nonrandomized study using historical controls
rom TAXUS ATLAS. Although the inclusion/exclusion
riteria of both studies were identical, the lack of random-
zation allows for imbalance in baseline characteristics.
lthough propensity score adjustments can partially com-
ensate for the lack of randomization, they cannot substi-
ute for randomization. Furthermore, because lesions cho-
en for direct stenting in this trial were carefully selected, the
esults might not apply to higher-risk lesions and patients
ot studied. Finally, although the reduction in TLR is
nteresting, the study was not powered to detect differences
n TLR.
onclusions
irect stent implantation with TAXUS Liberté is a feasible
nd highly successful technique for carefully selected lesions
f limited length and freedom from severe calcification.
irect stenting with TAXUS Liberté is noninferior to
tenting with pre-dilation in terms of 9-month %DS and
an significantly shorten procedure time, reduce proceduralomplications in simpler lesions, and might decrease reste-
osis and TLR rates.
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